Dyne Therapeutics (NASDAQ:DYN) Stock Rating Reaffirmed by Piper Sandler

Dyne Therapeutics (NASDAQ:DYN)‘s stock had its “overweight” rating reissued by stock analysts at Piper Sandler in a research note issued to investors on Monday, Benzinga reports. They currently have a $53.00 price objective on the stock. Piper Sandler’s price objective points to a potential upside of 58.68% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Guggenheim raised their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. JPMorgan Chase & Co. lifted their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 9th. StockNews.com downgraded Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, Oppenheimer reiterated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Trading Down 3.6 %

Dyne Therapeutics stock opened at $33.40 on Monday. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $47.45. The stock’s 50 day simple moving average is $40.68 and its two-hundred day simple moving average is $33.77. The firm has a market cap of $2.92 billion, a PE ratio of -8.41 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities research analysts forecast that Dyne Therapeutics will post -2.96 EPS for the current year.

Insider Activity

In other news, CEO John Cox purchased 32,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were bought at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction on Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the transaction, the director now directly owns 234,127 shares in the company, valued at approximately $8,533,929.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Cox bought 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was bought at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 132,947 shares of company stock worth $4,774,383. 20.77% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of DYN. RA Capital Management L.P. acquired a new stake in Dyne Therapeutics during the first quarter valued at $140,666,000. Janus Henderson Group PLC grew its stake in shares of Dyne Therapeutics by 23,512.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after purchasing an additional 2,663,910 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at approximately $15,758,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of Dyne Therapeutics by 8,284.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after acquiring an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Dyne Therapeutics by 47.7% in the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after acquiring an additional 1,110,629 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.